MOG and myeloid sarcoma: However, it has been suggested that low titers of MOG-IgG in a patient with MS may indicate that they lie on a disease spectrum between the two entities, in part because of the high proportion of patients with MS among those classified as false-positives in studies of MOG-IgG (75).